Essilorluxottica (OTC) ((ESLOY)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Essilorluxottica is currently recruiting participants for a clinical study titled ‘Algorithm-assisted Subjective Refraction Program Dedicated to Children.’ The study aims to address the lack of standardization in children’s refraction assessments by testing new software designed for use with Vision-S™ and Vision-R™ phoropters. This software targets children aged 6-12 and seeks to improve the accuracy and consistency of refraction results.
The study is testing two versions of the software: vA, which includes the steps for a complete subjective refraction process, and vB, which adds steps to help manage children’s attention and cooperation. These versions will be compared to conventional methods using the Vision-R™700 phoropter.
This interventional study is randomized with a parallel intervention model and single masking for participants. Its primary purpose is screening, aiming to validate the effectiveness of the new software in comparison to traditional methods.
The study began on June 12, 2025, with the last update submitted on June 23, 2025. These dates are crucial as they mark the study’s initiation and the latest information available, indicating the study’s progress and ongoing status.
For investors, this study could influence Essilorluxottica’s stock performance positively if the software proves effective, potentially setting a new standard in pediatric eye care. This could enhance their competitive edge in the optical industry, especially if competitors have not yet developed similar technology.
The study is ongoing, and further details are available on the ClinicalTrials portal.